Compare Incyte Corporation (INCY) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Snap On Incorporated — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Snap On Incorporated trades at $360.37 (market cap $18.56B). The key difference: Incyte Corporation is the larger of the two by market cap, and Snap On Incorporated pays a 2.72% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Snap On Incorporated for 37 Days on average.
| INCY | SNA | |
|---|---|---|
Market Cap | $22.85B | $18.56B |
Volume | 1,927,029 | 401,326 |
Sector | Health | Industrials |
52-Week High | $129.93 | $419.31 |
52-Week Low | $83.80 | $327.33 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $18.35B | $18.20B |
Dividend Yield | — | 2.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% today, with a bearish technical signal but strong fundamentals. The stock shows robust profitability with a 27.71% net income margin and 30.67% ROE. Recent news includes FDA approval for Atebrioz and expansion of its inflammation portfolio, supporting growth beyond its key drug JAKAFI. Revenue grew to $5.14 billion in 2025, with net income surging to $1.29 billion, reflecting improved operational efficiency.
The outlook is positive with a consensus price target of $132.43, implying 17% upside, though near-term earnings pressure and JAKAFI's patent expiry after 2029 pose risks. Analyst sentiment is bullish (52% buy ratings), but technical indicators suggest caution with key support at $111. Execution on pipeline diversification remains critical for sustained growth.
Snap-On Incorporated (SNA) trades at $358.88, down 0.28% with bearish technical signals from moving averages and oscillators. The company maintains strong fundamentals with 19.6% net income margin and 17.58% ROE, though Q1 2026 earnings missed expectations. Recent news highlights institutional position adjustments and gross margin expansion to 51.4% driven by RCI initiatives and volume growth.
Analyst consensus remains bullish with a $449 price target (66.7% buy ratings), but technical weakness and premium valuation create near-term headwinds. Key risks include integration costs from the Diesel Laptops acquisition and softer OEM demand, while strong cash flow generation and dividend payments provide shareholder value support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
